MA47166A - Polythérapie pour la stéatohépatite non alcoolique (shna) et la fibrose hépatique - Google Patents
Polythérapie pour la stéatohépatite non alcoolique (shna) et la fibrose hépatiqueInfo
- Publication number
- MA47166A MA47166A MA047166A MA47166A MA47166A MA 47166 A MA47166 A MA 47166A MA 047166 A MA047166 A MA 047166A MA 47166 A MA47166 A MA 47166A MA 47166 A MA47166 A MA 47166A
- Authority
- MA
- Morocco
- Prior art keywords
- nanhs
- polytherapy
- hepatic fibrosis
- alcoholic steatohepatitis
- steatohepatitis
- Prior art date
Links
- 206010019668 Hepatic fibrosis Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662439666P | 2016-12-28 | 2016-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47166A true MA47166A (fr) | 2021-05-19 |
Family
ID=61074511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047166A MA47166A (fr) | 2016-12-28 | 2017-12-28 | Polythérapie pour la stéatohépatite non alcoolique (shna) et la fibrose hépatique |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11160813B2 (fr) |
| EP (1) | EP3562490A1 (fr) |
| JP (1) | JP7175897B2 (fr) |
| KR (1) | KR20190103246A (fr) |
| CN (1) | CN110352059A (fr) |
| AU (1) | AU2017386648A1 (fr) |
| CA (1) | CA3047591A1 (fr) |
| IL (1) | IL267647A (fr) |
| MA (1) | MA47166A (fr) |
| MX (1) | MX2019007789A (fr) |
| PH (1) | PH12019501528A1 (fr) |
| TW (1) | TW201828989A (fr) |
| WO (1) | WO2018126016A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019374797A1 (en) * | 2018-11-08 | 2021-05-27 | Intercept Pharmaceuticals, Inc. | Methods of using obeticholic acid |
| US12551480B2 (en) | 2019-07-18 | 2026-02-17 | Enyo Pharma | Treatment using EYP001 |
| WO2021037702A1 (fr) * | 2019-08-28 | 2021-03-04 | Poxel | Combinaison pharmaceutique d'un dérivé de thiénopyridone spécifique avec un agoniste de fxr pour le traitement de maladies du foie |
| EP4192495A1 (fr) * | 2020-08-07 | 2023-06-14 | Bristol-Myers Squibb Company | Fgf21 combiné à des antagonistes de ccr2/5 pour le traitement de la fibrose |
| CN116829139A (zh) * | 2020-12-22 | 2023-09-29 | 北海医疗私人有限公司 | 用于治疗非酒精性脂肪性肝炎的包含含氧的结构增强的脂肪酸的联合治疗剂 |
| KR102591787B1 (ko) * | 2021-01-13 | 2023-10-20 | 한국과학기술원 | 키토산-빌리루빈 접합체를 포함하는 입자 및 이를 포함하는 약제학적 조성물 |
| JP2024510446A (ja) * | 2021-03-23 | 2024-03-07 | ダイメリックス バイオサイエンス ピーティーワイ リミテッド | 炎症性疾患の処置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106999593A (zh) | 2014-09-12 | 2017-08-01 | 妥必徕疗治公司 | 用于纤维化治疗的赛尼克韦罗组合疗法 |
| MX2018003179A (es) | 2015-09-16 | 2018-08-21 | Tobira Therapeutics Inc | Terapia de combinación con cenicriviroc para el tratamiento de fibrosis. |
-
2017
- 2017-12-28 CN CN201780081189.3A patent/CN110352059A/zh active Pending
- 2017-12-28 MX MX2019007789A patent/MX2019007789A/es unknown
- 2017-12-28 EP EP17835977.4A patent/EP3562490A1/fr not_active Withdrawn
- 2017-12-28 US US16/473,706 patent/US11160813B2/en not_active Expired - Fee Related
- 2017-12-28 JP JP2019536198A patent/JP7175897B2/ja active Active
- 2017-12-28 AU AU2017386648A patent/AU2017386648A1/en not_active Abandoned
- 2017-12-28 KR KR1020197022095A patent/KR20190103246A/ko not_active Ceased
- 2017-12-28 TW TW106146349A patent/TW201828989A/zh unknown
- 2017-12-28 MA MA047166A patent/MA47166A/fr unknown
- 2017-12-28 CA CA3047591A patent/CA3047591A1/fr not_active Abandoned
- 2017-12-28 WO PCT/US2017/068728 patent/WO2018126016A1/fr not_active Ceased
-
2019
- 2019-06-25 IL IL267647A patent/IL267647A/en unknown
- 2019-06-28 PH PH12019501528A patent/PH12019501528A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018126016A1 (fr) | 2018-07-05 |
| CN110352059A (zh) | 2019-10-18 |
| KR20190103246A (ko) | 2019-09-04 |
| MX2019007789A (es) | 2019-10-21 |
| EP3562490A1 (fr) | 2019-11-06 |
| PH12019501528A1 (en) | 2020-09-14 |
| TW201828989A (zh) | 2018-08-16 |
| US20190321377A1 (en) | 2019-10-24 |
| WO2018126016A8 (fr) | 2018-08-09 |
| AU2017386648A1 (en) | 2019-07-18 |
| CA3047591A1 (fr) | 2018-07-05 |
| US11160813B2 (en) | 2021-11-02 |
| JP7175897B2 (ja) | 2022-11-21 |
| IL267647A (en) | 2019-08-29 |
| JP2020504129A (ja) | 2020-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47166A (fr) | Polythérapie pour la stéatohépatite non alcoolique (shna) et la fibrose hépatique | |
| EP3347458A4 (fr) | Cochon multi-transgénique pour xénogreffe | |
| EP3471745A4 (fr) | Procédés et compositions pour réduire le stress oxydatif | |
| EP3630078A4 (fr) | Agents pour chimio-embolisation | |
| EP3467088A4 (fr) | Composition détergente liquide | |
| PT3368534T (pt) | Ditosilato de valbenazina e polimorfos do mesmo | |
| EP3408858A4 (fr) | Structures de graphène pour supercondensateurs | |
| EP3382683A4 (fr) | Afficheur | |
| GB201716855D0 (en) | Determining phonetic relationships | |
| EP3445701A4 (fr) | Distributeur post-mélange réfrigéré | |
| EP3610841A4 (fr) | Flacon compressible | |
| EP3404484A4 (fr) | Écran pour affichage | |
| DK3558278T3 (da) | Flydende cannabinoidsammensætning | |
| DK3532029T3 (da) | Flydende farmaceutisk sammensætning | |
| DK3496551T3 (da) | Flydende allulosesammensætning | |
| EP3339705A4 (fr) | Raccord fileté pour tubes | |
| EP3449930C0 (fr) | Agent de formation de synapses | |
| HUE054542T2 (hu) | Glükokortikoid receptor inhibitor | |
| EP3429690A4 (fr) | Procédés pour moduler keap1 | |
| EP3535061A4 (fr) | Buse microstructurée | |
| EP3286146A4 (fr) | Composition antiadhésive pour peinture et ses utilisations | |
| EP3730141A4 (fr) | Agent thérapeutique pour la pollakiurie nocturne | |
| EP3318577A4 (fr) | Anticorps agoniste d'antiplexine a1 | |
| EP3548516C0 (fr) | Anticorps trimérique à chaîne unique spécifique à cd33, cd16 et cd123 | |
| FR3020758B1 (fr) | Composition pour ameliorer l'hygiene buco-dentaire |